Abstract Details

Title Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?

Topic Multiple Sclerosis

Presentation(s) (-)

Poster/Presentation
Number 250

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Elisabeth Maillart PRESENTER	No disclosure on file
Celine Louapre, MD, PhD (Martinos Center for Biomedical Imaging)	No disclosure on file
Catherine Lubetzki (Hopital De La Salpetriere)	Catherine Lubetzki has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ROCHE. Catherine Lubetzki has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MERCK SERONO. Catherine Lubetzki has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for REWIND.
Caroline Papeix (GH Pitie Salpetriere)	Caroline Papeix has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BIOGEN . Caroline Papeix has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ROCHE . Caroline Papeix has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MERCK. Caroline Papeix has received personal compensation in the range of $0-$499 for serving as a Consultant for NOVARTIS .
	No disclosure on file

��ɫ��